Evidence map›Paper›PMID 30450049›Full record

ArticleFrontiers in pharmacology2018

Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells.

Kathrin Renner, Anton Seilbeck, Nathalie Kauer, Ines Ugele, Peter J Siska, Christina Brummer, Christina Bruss, Sonja-Maria Decking, Matthias Fante, Astrid Schmidt and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Differential regulation of mitochondrial uncoupling protein 2 in cancer cells.Biochimica et biophysica acta. Bioenergetics · 2024
    Article
  3. Research Progress on the Use of Metformin in Leukemia Treatment.Current treatment options in oncology · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Repression of LKB1 byCell reports. Medicine · 2020
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Kathrin RennerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Anton SeilbeckDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Nathalie KauerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Ines UgeleDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Peter J SiskaDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Christina BrummerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Christina BrussDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Sonja-Maria DeckingDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Matthias FanteDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Astrid SchmidtDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Kathrin HammonDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Katrin SingerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Sebastian KlobuchDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Simone ThomasDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Eva GottfriedDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Katrin PeterDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Marina KreutzDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accelerated metabolism of tumor cells, inevitable for maintaining high proliferation rates, is an emerging target for tumor therapy. Increased glucose and lipid metabolism as well as mitochondrial activity have been shown in solid tumors but also in leukemic cells. As tumor cells are able to escape the blockade of one metabolic pathway by a compensatory increase in other pathways, treatment strategies simultaneously targeting metabolism at different sites are currently developed. However, the number of clinically applicable anti-metabolic drugs is still limited. Here, we analyzed the impact of the anti-diabetic drug metformin alone or in combination with two non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac and diflunisal on acute myeloid leukemia (AML) cell lines and primary patient blasts. Diclofenac but not diflunisal reduced lactate secretion in different AML cell lines (THP-1, U937, and KG-1) and both drugs increased respiration at low concentrations. Despite these metabolic effects, both NSAIDs showed a limited effect on tumor cell proliferation and viability up to a concentration of 0.2 mM. In higher concentrations of 0.4-0.8 mM diflunisal alone exerted a clear effect on proliferation of AML cell lines and blocked respiration. Single treatment with the anti-diabetic drug metformin blocked mitochondrial respiration, but proliferation and viability were not affected. However, combining all three drugs exerted a strong cytostatic and cytotoxic effect on THP-1 cells. Comparable to the results obtained with THP-1 cells, the combination of all three drugs significantly reduced proliferation of primary leukemic blasts and induced apoptosis. Furthermore, NSAIDs supported the effect of low dose chemotherapy with cytarabine and reduced proliferation of primary AML blasts. Taken together we show that low concentrations of metformin and the two NSAIDs diclofenac and diflunisal exert a synergistic inhibitory effect on AML proliferation and induce apoptosis most likely by blocking tumor cell metabolism. Our results underline the feasibility of applying anti-metabolic drugs for AML therapy.

Indexed as

acute myeloid leukemiaAMLapoptosisdiclofenacdiflunisalmetabolismmetformin

Identifiers

PMID30450049
PMCPMC6224440
OpenAlexW2899464251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.